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High-dose chemotherapy with peripheral blood progenitor cell (PBPC) rescue has become an accepted option for treatment of relapsed or poor prognosis Hodgkin disease (HD) and non-Hodgkin's lymphomas (NHL). 1, 2 Although the combination of cyclophosphamide and G-CSF is usually used to mobilize PBPC, this scheme is, however, followed by significant toxicity. [3] [4] [5] For this reason many groups are using 'G-CSF alone' as mobilization therapy in patients with lymphomas: a therapy less costly and not associated with any morbidity. [6] [7] [8] [9] These two schemes have been compared in breast cancer 5, 10, 11 and multiple myeloma patients, 4, 5 and results showed a higher mobilization efficiency, in terms of harvested CD34+ cells, after cyclophosphamide and G-CSF.
In patients with lymphoma these two schemes have not always given similar results. In fact, in two studies, the amount of CD34+ cells harvested after these two regimens was similar, 12, 13 while other authors found a higher mobilizing capacity for the association 'cyclophosphamide plus G-CSF'. [14] [15] [16] Furthermore, when studied as second line mobilization therapy in patient failing a previous mobilization scheme, 'G-CSF alone' and 'cyclophosphamide plus G-CSF' have been considered of equivalent efficacy. 17, 18 We conducted a prospective randomized study with the aim of comparing results of 'cyclophosphamide plus G-CSF' and of 'G-CSF alone' as first mobilizing therapy in patients with Hodgkin's and non-Hodgkin's lymphomas.
Since previously administered chemotherapy is an important factor in success of mobilization, 9, 14, 19 we stratified patients according to the amount of chemotherapy previously received.
Patients and methods

Elegibility criteria and study design
In this study, we included 52 patients with HD and NHL who underwent PBPC mobilization treatment in our Institution from March 1998 to July 2002. Eligibility criteria were: age less than 70 years, a biopsyproven diagnosis of Hodgkin's or non-Hodgkin's lymphoma, normal left ventricular ejection fraction, DLCO greater than 60% of predicted value, normal renal function with a creatinine clearance 450 ml/min, bilirubin, aspartate aminotransferase and alanine transferase less than two times normal, no serological evidence of HIV, HCV or HBV infection; phase of disease was either first response with unfavourable prognostic factors or responding relapse. All patients were on their first mobilization attempt and no patients on second mobilization were included in this study. In all cases, a time interval of at least 6 weeks was required between last chemotherapy and start of mobilization treatment. During this time interval, criteria of eligibility were assessed, a complete restaging was performed and previous chemotherapy received by patients was quantified. Patients were divided into two categories depending on the number of lines of chemotherapy that they had received: patients who had received p2 lines of previous chemotherapy and those who had received 42 lines of previous chemotherapy. For the purpose of this study, each different chemotherapy regimen used was counted as one line of chemotherapy. Chemotherapy regimens were usually administered for number of cycles described in the original report.
Immediately before the start of mobilization treatment patients were randomized to receive PBPC mobilization using 'G-CSF alone' or 'cyclophosphamide plus G-CSF'. Patient assignment was stratified according to degree of previous pretreatment (p2 and 42 lines of previous chemotherapy).
Randomization list was generated, at the start of this study, using a specifically designed computer program (RND by S.S.O.S.B., Italy).
Patient characteristics
Patient characteristics studied are reported in Table 1 . The group receiving 'G-CSF alone' had a mean age of 37.3 years, while patients receiving 'G-CSF plus cyclophosphamide' had a mean age of 43.6 years (P ¼ 0.06). In stratum of more heavily pretreated patients, mean age of patients in the group receiving G-CSF was 43.6 and 50 years in the group of patients receiving 'cyclophosphamide plus G-CSF' (P ¼ 0.07). In the stratum of more pretreated patients, those receiving 'cyclophosphamide plus G-CSF' had in higher percentage a diagnosis of NHL with respect to group receiving 'G-CSF alone' (P ¼ 0.02). For all other variables, no significant differences were found. First line chemotherapies received by patients at diagnosis were the following disease-oriented regimens: ABVD (HD), MOPP/ABVD (HD), VACOP-B (NHL), CVP (lowgrade NHL); second line chemotherapies administered were the following regimens: MINE, IEV, ESHAP and FND.
Mobilization with 'G-CSF Alone'
Glycosylated-rh-G-CSF (Lenograstim) was employed at the dose of 10 mcg/kg/day administered in two daily doses by subcutaneous administration from day +1 to the end of harvesting.
Mobilization with 'cyclophosphamide plus G-CSF'
Cyclophosphamide was employed at a dose of 4 g/m 2 dissolved in 250 ml of 5% dextrose, by i.v. administration over 1 h on day +1, along with MESNA 3 g/m 2 by continuous infusion for 24 h. From day +4 after cyclophosphamide administration, glycosylated-rh-G-CSF (Lenograstim) was administered at a dose of 10 mg/kg/day in two daily doses by subcutaneous injection. This therapy was followed by antiinfectious prophylaxis using fluconazole and ciprofloxacin.
Collection of PBPC
Collections of PBPC were carried out using a cell separator (CS 3000 Plus-Baxter); the blood volume processed was double the calculated blood volume. In the majority of patients, venous access was obtained by a double lumen Hickman catheter placed in a central vein. The target number of CD34+ cells to be obtained in the apheretic harvests was 5.0 Â 10 6 /kg. Leukapheresis was started when the threshold value of CD34+ cells in the peripheral blood was over 20.0 Â 10 6 /l; patients reaching this threshold were considered 'successfully mobilized'. Nucleated cells (NC) counts were obtained by a Sysmex SF-3000 automated cell counter (Sysmex Corporation, Kobe, Japan).
'Total CD34+', 'Total NC' and 'Total CFU-GM' were obtained summing the value of the specified determination in all the aphereses performed in a single mobilization; 'CD34+ per apheresis', 'NC per apheresis' and 'CFU-GM per apheresis' were obtained dividing 'Total CD34+', 'Total NC' and 'Total CFU-GM' by the numbers of aphereses performed on each patient.
CD34+ analysis
The CD34+ cell count was determined by flow cytometry. Briefly, for immunofluorescence analysis, 1.0 Â 10 6 WBC from P.B. or from leukapheresis products were incubated for 15 min at room temperature with phycoerythris (PE)-conjugated class III monoclonal anti-CD34 antibody After incubation, erythrocytes were lysed with ammonium chloride buffer for 10 min. The cells were centrifuged at 600 g for 5 min, washed twice with PBS containing 0.1% sodium azide, and resuspended in 500 ml of PBS. Immunofluorescence analysis was performed using a FACScalibur (Becton Dickinson) equipped with argon laser at 488 nm and 0.3 W. For each sample, 100 000 cells were analysed. In a forward vs side scatter dot plot, a first region was set up to separate nucleated cells from debris. A second region limited by side scatter was set up to limit analysis to the MNC population. CD34+cells were identified and counted on another side scatter/PE dot plot, gated in both regions. For this purpose, CD34+ cells were defined by a highly fluorescent signal for PE and low side scatter.
The number of CD34+ cells per volume was calculated by multiplying the CD34 percentage obtained within the lympho-monocyte gate by leukocyte count obtained from a haematology analyser and dividing by 100.
CFU-GM culture
CFU-GM
(granulocyte-macrophage colony-forming units) were assayed in harvested PBPC by a culture test in methocellulose; 1 Â 10 5 cells were plated in medium enriched with growth factors (Methocult H04541, Stem Cell Technologies-Vancouver, Canada). Each sample was plated in triplicate, cultures were incubated at 371C in a humidified atmosphere of 5% CO 2 and scored under an inverted microscope after 10 days.
High-dose therapy and PBPC rescue
Patients reaching a minimum harvest of 2.0 Â 10 6 /kg. CD34+cells received high-dose therapy and PBPC rescue. In all cases, BEAM was used as the eradicating regimen. 20 Patients were nursed in single rooms and received antibacterial, antifungal and antiviral prophylactic treatment. Neutrophil (N.) engraftment was defined as the first day in which N. reached a count of at least 0.5 Â 10 9 /l, while Platelet (PLT) engraftment was defined as the first day of three consecutive days when the unsupported PLT count reached the value of 20.0 Â 10 9 /l.
Statistical analysis
Distribution of categorical variables was compared using the w 2 test or Fisher's exact test. Mean values for groups were compared using the t-test for normally distributed continuous variables such as age, and Mann-Whitney U-test for non-normally distributed continuous variables such as harvested CD34+, CFU-GM and NC. Correlations were studied using the Spearman Rank Test. Risk of reaching a Peak PB CD34+ value inferior to the median (23.3 Â 10 6 /l) was determined using logistic regression. To perform this analysis, all patients were categorized into two groups according to their P.B. Peak CD34+ values with respect to the median. This categorical variable was entered as a dependent variable, whereas age and mobilization type were entered as independent variables; the reference group was patients treated with 'cyclophosphamide plus G-CSF'.
Engraftment times were determined using survival methods, and results in different groups were compared using the log-rank test.
A statistics program (Statview, CA, USA) was utilized to record data and to perform all statistical analyses.
RESULTS
Percentage of successful mobilization
The percentage of the total patients which reached a CD34+ cell peak in peripheral blood superior to 20. 0 Â 10 6 /l, and therefore underwent harvesting of PBPC, was 50% (13/26) with 'G-CSF alone' mobilization and 61% (16/26) with 'cyclophosphamide plus G-CSF' ( Table 2) . The difference between percentages of mobilizing patients was not significant (w 2 test: P ¼ 0.4). In patients not heavily pretreated (p2 lines of chemotherapy), the percent successful mobilization was 68% (13/19) with 'G-CSF alone' and 64% (11/17) with 'cyclophosphamide plus G-CSF' (w 2 test: P4 0.8). In patients heavily pretreated (42 lines of chemotherapy), the percent successful mobilization was 0% (0/7) with 'G-CSF alone' and 55% (5/9) after 'cyclophosphamide plus G-CSF'. In patients heavily pretreated, the difference between percentages of successful mobilization using the scheme 'cyclophosphamide plus G-CSF' compared to 'G-CSF alone' was significant (P ¼ 0.01). /l in patients mobilized with 'G-CSF alone' and 48.8 Â 10 6 /l after 'cyclophosphamide plus G-CSF' (P ¼ 0.73).
Peak of CD34+ cells in peripheral blood
Conversely, in patients heavily pretreated (42 lines of chemotherapy) peak CD34+ cells obtained with 'G-CSF alone' was significantly lower than that with 'cyclophosphamide plus G-CSF' (10.9 Â 10 6 /l vs 40.2 Â 10 6 /l, P ¼ 0.05).
CD34+ cells, NC and CFU-GM in apheresis products
Results of 'Total CD34+ cells', 'Total NC', 'Total CFU-GM' and of 'CD34+ per apheresis', 'NC per apheresis' and 'CFU-GM per apheresis' are reported in Table 3 .
'Total CD34+ cells' harvested was 5.4 Â 10 6 /kg in patients mobilized with 'G-CSF alone' and 6.8 Â 10 6 /kg in those mobilized with 'cyclophosphamide plus G-CSF' (P40.9).
'Total NC' harvested was 5.7 Â 10 8 /kg in the group of patients mobilized with 'G-CSF alone' and 3.6 Â 10 8 /kg, in patients receiving 'cyclophosphamide plus G-CSF', and this difference was significant (P ¼ 0.008).
'Total CFU-GM' harvested was 3.5 Â 10 5 /kg in patients mobilized with 'G-CSF alone' and 4.1 Â 10 5 /kg in patients mobilized with 'cyclophosphamide plus G-CSF', difference was not significant (P ¼ 0.8).
No significant differences were detected in either 'Total CD34+' cells or in 'CD34+ per apheresis', when the stratum of patients pretreated with r2 lines of chemotherapy was considered. In the group of patients pretreated with 42 lines of chemotherapy, none had a successful mobilization using 'G-CSF alone'.
Mean number of aphaereses was 1.7, 1.6 and 2.0 for, respectively, the whole population of patients, patients not heavily pretreated and those who were heavily pretreated.
Factors related to CD34+ cell levels in peripheral blood
In the whole population of patients, a negative correlation (Figure 2 ) was observed between age and mean peak of CD34+ cells in peripheral blood (Spearman Rank correlation test, r ¼ À0.35, P ¼ 0.011).
No significant correlation was observed for time interval from last chemotherapy to mobilization and CD34+ cells peak in peripheral blood (Spearman Rank correlation test, r ¼ 0.02, P ¼ 0.88). In the group of patients pretreated with >2 lines of chemotherapy none had a successful mobilization using 'G-CSF alone'.
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In the whole population of patients, no differences were observed in peripheral blood CD34+ cells peaks for groups identified on the basis of sex (P ¼ 0.5), NHL or HD diagnosis (P ¼ 0.08), low grade-NHL diagnosis (P ¼ 0.1) and previous bone marrow involvement (P ¼ 0.6).
Multivariate analysis of the risk for a low CD34 peak
Since we found that age was significantly correlated with mobilization efficiency and since mean age was different in the two mobilization groups, we used multivariate analysis to study the risk of a low CD34+ cell peak associated, independently, with mobilization schemes and with age. Logistic regression showed that age (odds ratio: 1.081; Wald test: P ¼ 0.008; likelihood ratio test: P ¼ 0.05) and mobilization using 'G-CSF alone' (odds ratio: 3.383; Wald test: P ¼ 0.06; likelihood ratio test: P ¼ 0.05) increased, independently, the risk of obtaining a PB CD34+ peak below the median (23.3 Â 10 6 /l). However, when analysis was computed in the stratum of less heavily pretreated patients, only age was found to increase the risk of having a peak of CD34+ cells lower than the median value (odds ratio: 1.062; Wald test: P ¼ 0.05; likelihood ratio test: P ¼ 0.03), while no effect was attributed to 'G-CSF alone' (Wald test: P ¼ 0.6; likelihood ratio test: P ¼ 0.6).
Logistic regression was not computed in the more heavily pretreated group because of the small number of patients in this stratum.
Transplantation results in successfully mobilized patients
A total of 29/52 patients were successfully mobilized using one of the two regimens considered as first mobilization treatment and, from November 1998 to March 2002, 16/29 patients have already received high-dose therapy with PBPC rescue. All transplanted patients had engraftment and no regimen-related mortality was documented. Eight patients have been transplanted using G-CSF mobilized PBPC and eight patients using 'cyclophosphamide plus G-CSF' mobilized PBPC. The first group received a mean of 6.9 Â 10 Median time to reach a neutrophil count 40.5 Â 10 9 /l was 11.2 days (range 9-15) in the 'G-CSF alone' mobilized group and 11.8 days (range 10-16) in the 'cyclophosphamide plus G-CSF' mobilized group (log-rank test: P-value ¼ 0.5).
Median time to reach a platelet count420 Â 10 9 /l was 12.2 days (range [10] [11] [12] [13] [14] in the 'G-CSF alone' mobilized group and 14.5 (range 11-23) days in the 'cyclophosphamide plus G-CSF' mobilized group (log-rank test: P-value ¼ 0.33).
Possibility of obtaining a stem cell harvest in patients failing first mobilization
In total, 16 patients were successfully mobilized using 'cyclophosphamide plus G-CSF', while 10 patients did not experience a successful mobilization, seven patients received a second course of mobilization using chemotherapy (IEV, VP-16 as single agent or Cyclophosphamide 4 g/m 2 ) plus G-CSF, and 2/7 had a successful apheretic harvest. Thus, five patients out of seven also failed this second course of mobilization, and 4/5 underwent successful bone marrow harvesting. Overall, in the group receiving 'cyclophosphamide plus G-CSF' as first mobilization treatment, an adequate stem cell inoculum was, eventually, obtained in 22/26 patients (84%).
Overall, 13 patients were successfully mobilized using G-CSF alone, while 13 patients failed the first course of mobilization. In this group, 10 patients received a second course of mobilization using cyclophosphamide 4 g/m 2 plus G-CSF, and 4/10 had a successful apheretic harvest. Of the six patients who also failed the second mobilization course, four had a successful bone marrow harvest.
Overall, in the group receiving 'G-CSF alone' as first mobilization treatment, adequate stem cells for rescue were obtained in 21/26 patients (80%).
The difference in the overall percentage of patients reaching an adequate stem cell inoculum between groups in study was not significant (w 2 test: P-value ¼ 0.7).
Discussion
Peaks in P.B. of CD34+cells, percentage of successfully mobilized patients and contents of apheretic harvests did not differ, on univariate analysis, between the two groups treated with 'G-CSF alone' and with 'cyclophosphamide plus G-CSF'. However, in our study we also found, as recently reported by Gazitt et al, 19 that age is an important factor for efficiency of mobilization. We therefore used multivariate analysis to determine the efficiency of mobilization of 'G-CSF alone' and of 'cyclophosphamide plus G-CSF', taking into account the effect of age. Results showed that mobilization with 'G-CSF alone' has a higher probability of a CD34+ peak below the median. According to this analysis, 'cyclophosphamide plus G-CSF' has, indeed, higher mobilization efficiency than 'G-CSF alone', in accordance with reports by other authors.
14-16 A higher number of CD34+ cells after 'cyclophosphamide plus G-CSF' has been found by Meldgaard Knudsen et al, 16 the crossover design of this study allowed a high sensitivity in detecting differences between the two mobilization schemes.
A high CD34 + cell content in apheretic harvests was also found using 'cyclophosphamide 5 g/m 2 plus G-CSF' with respect to 'G-CSF alone' in a recently published study. 15 Some ways in which this study differs from ours should be pointed out: cyclophosphamide dose was higher, the threshold of CD34+ cells in P.B. used to start the apheresis was lower and the volume of blood processed was greater. The latter two points are the most likely explanations for the higher percentage of patients successfully harvested reported for both mobilization arms.
However, no differences in CD34+ cell contents of apheretic harvest after mobilization using 'cyclophosphamide plus G-CSF' and 'G-CSF alone' were reported by Cesana et al. 13 The relatively small size of this study may be the reason for failure to detect differences in the two mobilization schemes.
In the study of Kroger et al, 12 the same results of harvested CD34+ cells were obtained in lymphoma patients receiving chemotherapy plus G-CSF or 'G-CSF alone'. The therapy administered differed in that a very high dose of G-CSF was employed. Furthermore, the schedule of chemotherapy used included BCNU, a drug toxic to the haematopoietic stem cell, 9 which may, therefore, have impaired the process of mobilization in the arm where chemotherapy and G-CSF were combined.
No data are available in the literature comparing 'cyclophosphamide plus G-CSF' and 'G-CSF alone' in patients stratified according to degree of chemotherapy pretreatment.
In this study of patients with lymphoma who were not heavily pretreated, 'G-'CSF alone' gave, on univariate analysis, results comparable to 'cyclophosphamide plus G-CSF'. Multivariate analysis confirmed that, in this stratum of nonheavily pretreated patients, mobilization using 'G-CSF alone' did not increase the risk of a CD34+ cell peak in the P.B. being below the median, and therefore of an unsuccessful mobilization, even when the effect of age was taken into account.
Conversely, a higher mobilization efficiency with the association 'cyclophosphamide plus G-CSF' was evident on univariate analysis, in both peak of CD34+ cells and percentage of successfully mobilized patients when the stratum of more heavily pretreated patients was examined. In fact, in this stratum these parameters were lower using 'G-CSF alone' compared to 'cyclophosphamide plus G-CSF'.
The lower mobilization efficiency of 'G-CSF alone' in the stratum of more heavily pretreated patients may have practical implications in the choice of a mobilizing scheme. In heavily pretreated patients, the use of 'cyclophosphamide plus G-CSF' may be preferable since this yields a substantially higher probability of successfully mobilization.
However, apart from the number of CD34+ cells harvested, other issues should be considered in evaluating a mobilization scheme.
First, although the number of CD34+ cells is recognized as important in evaluating engraftment potential after autologous PBPC transplants, CD34+ cells are nevertheless heterogeneous, and some subsets of CD34+ cells could be more important than others. CD34+ cells obtained from PB after different mobilization schemes show differences in surface antigens 12, 21 which could imply different CD34+ subpopulation distributions and hence different engraftment potentials. In this regard it is important to note that in studies comparing 'cyclophosphamide plus G-CSF' and 'G-CSF alone', different amounts of CD34+ cells were obtained even though engraftment times were the same with both mobilizing schemes. 4, 15 Our own clinical experience, although limited because of the smaller number of patients who have been transplanted to date using PBPC harvested during a first mobilization, is in accordance with these results.
Besides mobilizing efficiency and engraftment potential, other factors should be taken into consideration as clinically important. One of these is neoplastic contamination of PBPC. The importance of neoplastic contamination of infused stem cells in patients with lymphomas is still an unresolved issue. The usefulness of purging has been demonstrated in patients with follicular lymphomas, 22 while the importance of neoplastic contamination in patients with other types of lymphoma has not been so clearly shown. 23 Lymphoma cells circulate in P.B. in many patients, 24, 25 and they can be mobilized by current mobilization strategies; 24 however, the seeding efficiency of these cells and hence their role in determining relapse after autologous transplantation is not clear. 26, 27 Tumour cell contamination of apheretic harvests obtained after 'cyclophosphamide plus G-CSF' or after 'G-CSF alone' has been studied in patients with breast cancer and in patients with lymphomas and no differences have been detected. 11, 15, 28 'G-CSF alone', compared to 'cyclophosphamide plus G-CSF', results in apheretic harvests with a higher content of nucleated cells and lymphocytes; furthermore, a fast immune recovery has been reported after autologous transplantation of PBPC harvested using 'G-CSF alone'. 29 Such a rapid immune system recovery could have a beneficial effect on long-term results of high-dose therapy and autologous transplantations. In fact, it has recently been reported that after autologous PBPC transplants, an early immune system recovery is associated with a better outcome. 30 Finally, it should be considered that in our study many patients failing the first mobilization treatment were 'rescued' by a second mobilization course or by bone marrow harvesting. Thus, overall, comparable results were obtained in terms of the number of patients who could eventually have an adequate inoculum and could receive high-dose therapy, and this regardless of which of the two mobilization schemes was first employed.
We conclude, therefore, that 'cyclophosphamide plus G-CSF' has, in the population of patients studied as a whole, statistically higher mobilization efficiency. This superiority is however limited to the stratum of patients who had previously received heavier chemotherapy treatment. In such patients, therefore, the combination of 'cyclophosphamide plus G-CSF' may be preferable, given the significantly higher probability of successful mobilization.
In less heavily pretreated patients, no mobilizing advantage of 'cyclophosphamide plus G-CSF' was apparent in our study, although it is possible that this advantage may be detectable if a larger number of patients is studied.
Nevertheless, since 'G-CSF alone' shows good mobilization efficacy with no evidence of a higher risk of neoplastic contamination, and offers the advantages of low cost, low morbidity and fast immune recovery, in this patient subset it can be considered an adequate mobilization approach.
Further comparison between these two mobilization regimens must be undertaken in wider studies so that any possible differences in survival offered by these two schemes may be fully apparent.
In the area of HSC mobilization there is need for further studies directed at ensuring an improvement in the harvested PBPC product for as many patients as possible, and at achieving this goal without the toxicity of chemotherapy. 31 
